A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients
Authors:
- Andrea Emanuele GueriniAGAndrea Emanuele Guerini
- Sara PedrettiSPSara Pedretti
- Emiliano SalahESEmiliano Salah
- Edda Lucia SimonciniESEdda Lucia Simoncini
- Marta MaddaloMMMarta Maddalo
- Ludovica PegurriLPLudovica Pegurri
- Rebecca PedersiniRPRebecca Pedersini
- Lucia VassalliLVLucia Vassalli
- Nadia PasinettiNPNadia Pasinetti
- Gloria PerettoGPGloria Peretto
- Luca TriggianiLTLuca Triggiani
- Gianluca CostantinoGCGianluca Costantino
Open Access
- 12 August 2020
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-8
Abstract
Cyclin dependent kinases 4/6 (CDK4/6) inhibitors gained an essential role in the treatment of metastatic breast cancer. Nevertheless, data regarding their use in combination with radiotherapy are still scarce. We performed a retrospective preliminary analysis of breast cancer patients treated at our Center with palliative radiation therapy and concurrent CDK4/6 inhibitors. Toxicities were measured according to CTCAE 4.0, local response according to RECIST 1.1 or PERCIST 1.0 and pain control using verbal numeric scale. 18 patients (32 treated sites) were identified; 50% received palbociclib, 33.3% ribociclib and 16.7% abemacliclib. Acute non-hematologic toxicity was fair, with the only exception of a patient who developed G3 ileitis. During 3 months following RT, 61.1% of patients developed G 3–4 neutropenia; nevertheless no patient required permanent suspension of treatment. Pain control was complete in 88.2% of patients three months after radiotherapy; 94.4% of patients achieved and maintained local control of disease. Radiotherapy concomitant to CDK4/6 inhibitors is feasible and characterized by a fair toxicity profile, with isolated episodes of high-grade reversible intestinal toxicity. Rate of G 3–4 neutropenia was comparable with that measured for CDK4/6 inhibitors alone. Promising results were reported in terms of pain relief and local control of disease.Keywords
This publication has 38 references indexed in Scilit:
- Inhibition of CDK4/CDK6 Enhances Radiosensitivity of HPV Negative Head and Neck Squamous Cell CarcinomasInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2019
- Enhanced dermatologic toxicity following concurrent treatment with palbociclib and radiation therapy: A case reportReports of Practical Oncology and Radiotherapy, 2019
- Blocking Cyclin-Dependent Kinase 4/6 During Single Dose Versus Fractionated Radiation Therapy Leads to Opposite Effects on Acute Gastrointestinal Toxicity in MiceInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2018
- Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia–mutated kinase–mediated DNA damage responseEuropean Journal of Cancer, 2018
- Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trialBreast Cancer Research and Treatment, 2017
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast CancerJournal of Clinical Oncology, 2017
- Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric studyBritish Journal of Cancer, 2017
- Inhibition of CDK4/6 protects against radiation-induced intestinal injury in miceJournal of Clinical Investigation, 2016
- Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid TumorsCancer Discovery, 2016
- Palliative Radiotherapy for Bone Metastases: An ASTRO Evidence-Based GuidelineInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011